Human Genome Sciences (HGSI) Climbs Higher On Takeover Speculation

Shares of Human Genome Sciences Inc. (Nasdaq: HGSI) are continuing to climb higher today and traders are chatting about a potential takeover of the company. Shares are up 6.5% currently.

Speculators are pointing to the Piper Jaffray research report this morning,�in which the firm raised their price target on HGSI from $15 to $25. The comment that has speculators salivating was "if BLISS-76 data is positive, we see a real chance that partner GlaxoSmithKline (NYSE: GSK)acquires HGS." The firm notes GSK shares Benlysta and daraplatib for the treatment of atherosclerosis, and has rights to Syncria for diabetes. They also said HGS has a history of significant net operating loss (NOLs) that they see as a "tax-free coupon" for a potential acquirer.

Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php

You May Also Be Interested In

• JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
• JPMorgan Downgrades Kuaishou Technology (1024:HK) to Neutral
• JPMorgan Downgrades Bowman Consulting Group Ltd. (BWMN) to Underweight